Everardo D Saad

Summary

Publications

  1. ncbi Endpoints in advanced breast cancer: methodological aspects & clinical implications
    Everardo D Saad
    Dendrix Research, Sao Paulo, Brazil
    Indian J Med Res 134:413-8. 2011
  2. ncbi Progression-free survival and time to progression as primary end points in advanced breast cancer: often used, sometimes loosely defined
    E D Saad
    Dendrix Research, Sao Paulo, Brazil
    Ann Oncol 20:460-4. 2009
  3. ncbi The geography of clinical cancer research: analysis of abstracts presented at the American Society of Clinical Oncology Annual Meetings
    E D Saad
    Dendrix Research Ltd, Sao Paulo, Brazil
    Ann Oncol 21:627-32. 2010
  4. ncbi Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature
    E D Saad
    Dendrix Research, Hospital Sirio Libanes, Sao Paulo, Brazil
    Ann Oncol 21:7-12. 2010
  5. ncbi Overall survival and post-progression survival in advanced breast cancer: a review of recent randomized clinical trials
    Everardo D Saad
    Dendrix Research, Rua Joaquim Floriano, 72 24 Sao Paulo, Brazil 04534 000
    J Clin Oncol 28:1958-62. 2010
  6. ncbi Primary systemic chemotherapy of invasive lobular carcinoma of the breast
    Artur Katz
    Centro Paulista de Oncologia and Hospital Albert Einstein, Sao Paulo, Brazil
    Lancet Oncol 8:55-62. 2007

Detail Information

Publications6

  1. ncbi Endpoints in advanced breast cancer: methodological aspects & clinical implications
    Everardo D Saad
    Dendrix Research, Sao Paulo, Brazil
    Indian J Med Res 134:413-8. 2011
    ..This brief review aims at helping clinicians in their daily need to interpret the literature and make informed treatment choices for patients with advanced breast cancer...
  2. ncbi Progression-free survival and time to progression as primary end points in advanced breast cancer: often used, sometimes loosely defined
    E D Saad
    Dendrix Research, Sao Paulo, Brazil
    Ann Oncol 20:460-4. 2009
    ..Background: The growing availability of active agents makes the development of novel therapies increasingly complex and the choice of end points critical. We assessed the frequency of use of efficacy end points in advanced breast cancer...
  3. ncbi The geography of clinical cancer research: analysis of abstracts presented at the American Society of Clinical Oncology Annual Meetings
    E D Saad
    Dendrix Research Ltd, Sao Paulo, Brazil
    Ann Oncol 21:627-32. 2010
    ..The American Society of Clinical Oncology Annual Meeting is the largest forum for presentation of clinical research in oncology. We quantified the contribution of countries and assessed correlates of their presence at such meetings...
  4. ncbi Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature
    E D Saad
    Dendrix Research, Hospital Sirio Libanes, Sao Paulo, Brazil
    Ann Oncol 21:7-12. 2010
    ..The other question is whether PFS sufficiently reflects clinical benefit to be considered a true end point in and of itself...
  5. ncbi Overall survival and post-progression survival in advanced breast cancer: a review of recent randomized clinical trials
    Everardo D Saad
    Dendrix Research, Rua Joaquim Floriano, 72 24 Sao Paulo, Brazil 04534 000
    J Clin Oncol 28:1958-62. 2010
    ..PPS represents nearly two thirds of patient survival after on-trial disease progression...
  6. ncbi Primary systemic chemotherapy of invasive lobular carcinoma of the breast
    Artur Katz
    Centro Paulista de Oncologia and Hospital Albert Einstein, Sao Paulo, Brazil
    Lancet Oncol 8:55-62. 2007
    ..Invasive lobular carcinoma deserves to be investigated separately in prospective clinical trials to define the best treatment and prevention strategies...